| ASSET | QUARTER | % RETURN |
|---|---|---|
Viking Therapeutics (VKTX) | Q1 2020 | -43.27% |
Viking Therapeutics (VKTX) | Q2 2020 | 65.75% |
Viking Therapeutics (VKTX) | Q3 2020 | -18.72% |
Viking Therapeutics (VKTX) | Q4 2020 | -3.26% |
Viking Therapeutics (VKTX) | Q1 2021 | 10.96% |
Viking Therapeutics (VKTX) | Q2 2021 | -5.67% |
Viking Therapeutics (VKTX) | Q3 2021 | 3.8% |
Viking Therapeutics (VKTX) | Q4 2021 | -26.52% |
Viking Therapeutics (VKTX) | Q1 2022 | -35.76% |
Viking Therapeutics (VKTX) | Q2 2022 | -3.99% |
Viking Therapeutics (VKTX) | Q3 2022 | -5.56% |
Viking Therapeutics (VKTX) | Q4 2022 | 240.58% |
Viking Therapeutics (VKTX) | Q1 2023 | 81.18% |
Viking Therapeutics (VKTX) | Q2 2023 | -3.66% |
Viking Therapeutics (VKTX) | Q3 2023 | -31.11% |
Viking Therapeutics (VKTX) | Q4 2023 | 69.18% |
Viking Therapeutics (VKTX) | Q1 2024 | 342.53% |
Viking Therapeutics (VKTX) | Q2 2024 | -35.33% |
Viking Therapeutics (VKTX) | Q3 2024 | 18.6% |
Viking Therapeutics (VKTX) | Q4 2024 | -36.35% |
Viking Therapeutics (VKTX) | Q1 2025 | -40.72% |
Viking Therapeutics (VKTX) | Q2 2025 | 15.24% |
